GleamWall
中文EN

APUS Apimeds Pharmaceuticals US, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1894525 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-341.0%
TTM EPS YoY-84.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-30.6%
ROA-27.9%
ROIC (approx.)-26.2%
Asset turnover—

Leverage & solvency

Liabilities / assets8.5%
Debt / equity0.00x
Current ratio0.83x
Interest coverage-4.35x

Cash quality & payout

Operating cash flow / net income0.52x
Accruals ratio-13.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$2.90M$282,732——————
Cost of revenue$54,300———————
Gross profit$2.84M———————
R&D expense—$959,742$901,144$361,104$619,693$651,784——
SG&A expense$814,477$5.32M$11.28M$6.68M$1.22M$2.01M$364,368$275,613
Operating income$2.03M-$6.28M-$12.19M-$7.04M-$1.84M-$2.66M-$364,368-$275,613
Interest expense$1.09M$3.22M$859,405$215,624$6,301$23,054$38,032$36,050
Net income$33.65M-$20.17M-$35.06M-$1.16M-$1.78M-$2.66M-$402,397-$311,633
EBITDA$2.03M-$6.27M-$12.17M-$7.04M-$1.84M-$2.66M——
EPS (basic)19.13-11.77-2.26—-1.42-2.57-0.05—
EPS (diluted)7.68-11.77-2.26—-1.42-2.57-0.05—
Weighted avg. shares (diluted)4.48M1.71M15.51M—1.26M1.04M7.90M—
Banking
Deposits———$8.00M————
Balance sheet
Cash & equivalents$17,912$278,371$979,534$144,601$6.99M$8.74M$250,432$3,455
Short-term investments——$1.50M$2.00M————
Receivables$2.48M———————
Current assets$10.85M$10.68M$13.15M$13.98M$9.09M$10.35M$259,904$13,057
PP&E, net—$51,929$56,592$51,626$34,188$13,137——
Total assets$153.53M$127.62M$141.22M$164.18M$9.25M$10.55M$259,904$13,057
Current liabilities$13.01M$21.07M$14.58M$10.71M$1.09M$809,002$1.77M$1.02M
Total liabilities$13.01M$21.18M$14.70M$10.84M$1.09M$809,002$2.02M$1.37M
Shareholders' equity$140.52M$106.45M$126.52M$153.35M$8.16M$9.74M-$1.76M-$1.36M
Shares outstanding1.85M1.51M12.58M1.26M12.58M12.58M7.90M7.90M
Cash flow statement
Operating cash flow-$218,617-$5.67M-$2.07M-$3.82M-$1.73M-$3.36M-$20,313-$99,616
Capital expenditure$0$0$9,394$21,424$22,540———
Free cash flow-$218,617-$5.67M-$2.08M-$3.84M-$1.75M———
Investing cash flow-$53,186$1.50M$490,606-$10.02M-$22,540———
Financing cash flow$11,345$3.47M$920,000$8.49M$0$11.86M$267,200$76,500
Depreciation & amortization$0$4,662$20,044$3,985$1,489$232——
Stock-based compensation-$1,051$105,210—$1.33M$42,674$192,053$0—

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.